Cambridge, United Kingdom, Langenhagen, Germany, and San Antonio, Texas – August 10, 2009 – Lab21 Ltd and AdnaGen AG announced today that they have entered into an exclusive service and distribution agreement for AdnaGen’s proprietary CE-certified circulating tumor cell diagnostic assays in the United Kingdom and Ireland. These tests are based on the capture of circulating tumor cells (CTCs) from blood and subsequent detection of tumor-associated biomarkers.

San Antonio, TX, --- July 23, 2009 – OncoVista Innovative Therapies, Inc. (“OncoVista”) (OTC BB: OVIT.OB)  and AdnaGen AG announced that The University of Texas M. D. Anderson Cancer Center will collaborate on clinical studies of AdnaGen’s molecular based CTC technology in Women with High-Risk Locally Advanced Breast Cancer (LABC) that have completed Neoadjuvant and Local Therapy.

Eliminates over four million Euros in debt from balance sheet

San Antonio, Texas and Hanover, Germany - May 4, 2009 - AdnaGen AG announced today the completion of its debt restructuring efforts.

AdnaGen AG, developer and marketer of blood test diagnostics kits for the identification and molecular analysis of circulating tumor cells, substantially reduced its debt by exchanging €4.2 million of debt and related accrued interest for equity. This event is a significant milestone in completing the financial turn-around and corporate renewal for AdnaGen. OncoVista, Inc., AdnaGen’s 95% majority shareholder, together with financial investors Technologie-Beteiligungs-Gesellschaft mbH, Mittelstandische Beteilgungsgesellschaft Niedersachsen and Biomed Venture GmbH joined forces to position AdnaGen with the ability to secure additional financing to support the Company’s growth strategy

Cancer Therapy & Research Center at The University of Texas Health Science Center and OncoVista Innovative Therapies, Inc. Announce the Initiation of Collaboration on the Clinical Development of OVI-117